ExonHit chosen to join the European Innovative Medicines Initiative consortium on Alzheimer’s disease
ExonHit Therapeutics S.A. announced that it has been chosen to participate in the European Innovative Medicines Initiative (IMI) consortium focused on identifying biomarkers for Alzheimer’s disease (PharmaCog). PharmaCog focuses on translational science and harmonization of research tools. Ultimately PharmaCog should provide the tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines.
PharmaCog stands for “Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development”. It is a cross party project, cocoordinated by GlaxoSmithKline R&D and the Université de la Méditerranée, Marseille, France. It brings together top scientists from 5 small and medium size enterprises, 11 global pharmaceutical companies, 12 academic institutions; in addition, 1 patient group representing 9 countries across Europe will ensure the dissemination of PharmaCog results. The European Medicines Agency (EMA), an associated partner of the project, will share project progress and discuss the implications for drug development in Europe.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.